Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR(R) artificial intelligence (“AI””) and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, will be participating in the upcoming RHK Capital Disruptive Growth Conference. Slated for Dec. 5, 2022, the conference will be held in New York City. During the conference, Lantern Pharma CEO and president Panna Sharma will present; his presentation is scheduled for 12 p.m. ET. The RHK Capital Disruptive Growth Conference brings together leading C-suite executives and senior management from up to 30 growth-oriented and disruptive companies with a wide array of members from the investment community, including seasoned institutional investors, accredited investors, representatives of family offices, market analysts, financial advisors, broker-dealer wealth managers and select RHK clients.
To view the presentation, visit https://ibn.fm/zlGSU
To view the full press release, visit https://ibn.fm/63v0X
About Lantern Pharma Inc.
Lantern Pharma is a clinical-stage, oncology-focused biopharmaceutical company leveraging its proprietary RADR AI and machine-learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across 11 disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern’s approach represents the potential to deliver best-in-class outcomes. To learn more about the company, visit www.LanternPharma.com
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork